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lead compounds in gene regulation [9] and immunomodulation therapies. [10, 11] The 3D architecture of the SNA, rather than the chemical composition of the nanoparticle (NP) core, is the origin of many of the biochemical properties that make them exceedingly useful in the life sciences and medicine. [1, 12] Therefore, to realize the full clinical potential of the SNA construct, recent efforts have focused on designing novel constructs from biocompatible, organic NP cores, including liposomes, [13] proteins, [14] and polymeric micelles [11, [15] [16] [17] [18] that add additional functionality and lead to therapeutic advantages.
For many combination therapies, the ideal SNA should exhibit the following properties. First, it should consist of a biocompatible, biodegradable organic core capable of carrying and temporally releasing drugs in a tunable fashion. Second, it should contribute to the long-term stability of the nucleic acid shell so that the chemical and biophysical properties of such a construct can be retained under challenging physiological conditions. Finally, it should be straightforward to synthesize in a scalable manner.
With these considerations in mind, poly(lactic-co-glycolic acid) (PLGA) is an attractive material as the core for SNAs. It is biocompatible and biodegradable, [19, 20] relatively stable, [21] and exhibits composition-dependent and therefore tunable release kinetics for encapsulated cargos. [22] [23] [24] Herein, we report a facile synthetic strategy for the preparation (Scheme 1) of PLGA-SNAs from 50 nm diameter PLGA particle cores [25] terminated with azides and oligonucleotides terminated with the dibenzocyclooctyne (DBCO) group via Cu-free click chemistry. Note that others have made nucleic acid-PLGA conjugates (an aptamer-PLGA nanoconstruct) for targeting purposes, [22, 26] prior to the understanding of the SNA architecture (not simply nucleic-nanoparticle conjugates) and its important role in facilitating scavenger receptor A mediated cellular uptake. In a typical particle preparation procedure, PLGA-PEG-N 3 (poly(lactide-co-glycolide)-b-poly(ethylene glycol)-azide)/PLGA (M w = 38 000-42 000 Da, polylactic acid (PLA): polyglycolic acid (PGA) = 50:50) (20% w/w) was dissolved in acetonitrile and injected dropwise into water under rapid mixing, resulting in 45-150 nm diameter PLGA-PEG-N 3 NPs, depending upon the polymer concentration in acetonitrile (Figure S1, Supporting Information). Since nanostructures with diameters less than 100 nm are believed to reach tumor sites, penetrate tumor tissues, and enter cancer cells via the enhanced permeability and retention effect, [27] we used synthetic conditions that yielded NPs with a hydrodynamic diameter of ≈50 nm for all studies described herein. Next, five mole equivalents of DBCO-modified A new class of polymer spherical nucleic acid (SNA) conjugates comprised of poly(lactic-co-glycolic acid) (PLGA) nanoparticle (NP) cores is reported. The nucleic acid shell that defines the PLGA-SNA exhibits a half-life of more than 2 h in fetal bovine serum. Importantly, the PLGA-SNAs can be utilized to encapsulate a hydrophobic model drug, coumarin 6, which can then be released in a polymer composition-dependent tunable manner, while the dissociation rate of the nucleic acid shell remains relatively constant, regardless of core composition. Like prototypical gold NP conjugate SNAs, PLGA-SNAs freely enter Raw-Blue cells and can be used to activate toll-like receptor 9 in a sequence-and dose-dependent manner. Taken together, the data show that this novel nanoconstruct provides a means for controlling the release kinetics of encapsulated cargos in the context of the SNA platform, which may be useful for developing combination therapeutics.
DNA Nanotechnology
Spherical nucleic acids (SNAs) are a class of nanoconjugates that are overcoming challenges that face current nucleic acid therapies. They provide privileged access at both the cellular and tissue levels. For example, SNAs are actively transported across cell membranes by engaging class A scavenger receptors [1, 2] while unmodified linear nucleic acids do not enter cells in significant amounts without the use of transfection agents. [3, 4] In addition, the polyvalent, densely functionalized nucleic acid shell that defines an SNA can act as a high affinity binder for different classes of ligands, including certain receptor proteins [1] and complementary nucleic acid sequences. [5] Consequently, SNAs have emerged as a powerful platform for developing molecular diagnostic probes [6] [7] [8] and as www.advmat.de www.advancedsciencenews.com oligonucleotides were added to PLGA-PEG-N 3 NPs in a buffer solution containing 0.5 m NaCl with 0.3% (v/v) Poloxamer 188 in 1X phosphate buffered saline. The reaction mixture was then incubated at 25 °C for 48 h. The unreacted nucleic acids were separated from the target PLGA-SNAs by passing them through an Amicon filter (size cutoff = 100 K). The purified SNA product was collected from the filter and analyzed by 1% agarose gel electrophoresis ( Figure S2A , Supporting Information). The linear nucleic acids and PLGA-SNAs exhibit different electrophoretic mobility shifts due to size and charge. In addition, consistent with DNA functionalization of the PLGA NP core, the average SNA diameter, determined by dynamic light scattering (DLS), is ≈15 nm larger than the unfunctionalized core (50 nm for PLGA-PEG-N 3 , polydispersity index (PDI) = 0.088; 65 nm for PLGA-SNAs, PDI = 0.131, Figure 1B) . The PLGA-PEG-N 3 NPs and PLGA-SNAs were imaged by atomic force microscopy (AFM) in the liquid phase, allowing us to visualize the solution-phase NPs and obtain quantitative size distributions ( Figure 1A Since the surface density of oligonucleotides on SNAs affects many of their biochemical properties, [12] the average number of strands per SNA conjugate was determined by making PLGA-SNAs with Cy5-tagged T 20 both particle size and absolute number of DNA strands by using fluorescence spectroscopy methods. After NP isolation and purification, the NPs were redispersed in buffer, diluted in water, and the concentration was measured with a Nanoparticle Tracking Analysis system ( Figure S3A , Supporting Information). The oligonucleotide concentration was measured by first dissolving the PLGA core of the SNA, which results in release of the oligonucleotides that define the shell, and quantifying and comparing the Cy5 fluorescence against a standard curve ( Figure S3B , Supporting Information). Each ≈65 nm (50 nm core) PLGA-SNA has an average of 199 ± 16 strands or a surface density of 5.2 pmole cm −2 . We note that this surface density is lower than a typical 13 nm Au SNA, where the surface density is ≈30 pmol cm −2 , [28] but greater than liposomal SNAs (≈3.2 pmol cm −2 ), [13] which also have been taken into the clinical trials. [29] The cooperative binding of SNAs is a direct consequence of their high nucleic acid surface coverage. Indeed, when PLGA-SNAs are incubated with a batch of 13 nm Au SNAs bearing a complementary sequence, a red precipitate forms, which is due to polymerization via DNA hybridization ( Figure 1D ). Consistent with this observation, this precipitate exhibits a sharp melting transition when heated above the melting temperature of the DNA (full-width at half-maximum ≈4 °C, Figure S4 , Supporting Information), characteristic of SNAs.
NPs made of soft materials have been utilized to encapsulate a wide range of drugs, such as chemotherapy agents and nucleic acids. Furthermore, codelivery of such agents within one nanoscale entity has been shown to enhance therapeutic efficacy in certain cases. [30] However, a challenge with such combination therapy strategies pertains to how one can precisely control the temporal release of both drugs independently Adv. Mater. 2018, 30, 1707113 www.advmat.de www.advancedsciencenews.com so that therapeutic effects can be maximized. Additionally, encapsulating both hydrophobic and hydrophilic drugs in one entity often results in poor drug-loading efficiencies, [31] involves complicated preparation processes, [32] and can lead to a significant increase in NP size. [33] The PLGA-SNA construct can spatially compartmentalize a chemotherapy drug and therapeutic nucleic acids in a single entity, so the loading and release of surface-conjugated nucleic acids and encapsulated drugs can be independently controlled. We hypothesize that by varying the chemical composition of the PLGA polymer, the release kinetics of the encapsulated drugs can be tuned, while the release rates of the nucleic acid shell remain relatively constant. To investigate the release profiles of the nucleic acids on the surface of PLGA-SNAs, we synthesized three batches of PLGA-SNAs with different polymer core compositions based on different molecular weights and molar ratios of PLA to PGA, namely RG 502, RG 504, and RG 756 S ( Table 1) . The sizes of PLGA-SNAs prepared from such polymers are relatively close (± 10 nm), suggesting that the NP size attained during nanoprecipitation does not depend significantly on the chemical composition of the polymer (Figure S5A , Supporting Information).
The release profiles of the nucleic acids on the PLGA-SNAs were investigated by utilizing a fluorescence turnon experiment where the PLGA-SNA core and the 15-mer oligonucleotides were labeled with rhodamine and Cy5 (Figure 2A) , creating a Förster resonance energy transfer (FRET) PLGA-SNA. The dissociation of the nucleic acid shell was evaluated in 10% fetal bovine serum (FBS). When the nucleic acids are released from the surface of PLGA-SNAs, the rhodamine fluorescence (λ em = 573 nm) increases, while the Cy5 fluorescence (λ em = 670 nm) decreases ( Figure 2B ). The release profiles of the nucleic acid shell for all three PLGA-SNAs are similar, exhibiting half-lives of more than 2 h with K obs ranging from 7.4 × 10 −5 to 8.8 × 10 −5 s −1 ( Figure 2C , Table 1 ). These K obs values suggest that PLGA-SNAs are nearly 100-fold more stable than the most clinically advanced liposomal SNAs and three times more stable than the lipid-tail SNAs (K obs = 7.9 × 10 −3 s −1 and 2.8 × 10 −4 s −1 for liposomal SNA and lipid-tail LSNAs, respectively). [34] The increased stability of the PLGA-SNAs are likely due to the covalent bond utilized to immobilize the nucleic acids on the NPs and the intrinsically higher stability of polymer NPs (as compared with liposomes). Additionally, nucleic acids conjugated to the PLGA NP also exhibited increased stability against DNase I degradation, as compared to the linear counterparts ( Figure S6 , Supporting Information). The enhanced stability of these SNAs will likely make them last longer under physiological conditions, potentially leading to increased therapeutic efficacies in certain settings (e.g., systemic use).
Next, we investigated the release kinetics of coumarin 6, a commonly used fluorescent, hydrophobic model drug, encapsulated within the PLGA-SNAs. To load coumarin 6 into the polymer matrix, it (0.5% (w/w)) was codissolved with PLGA in acetonitrile ( Figure S5B , Supporting Information), and the mixture was injected into water to form the particles via the precipitation method. These structures were converted into SNAs via the procedure described above. The percent release is determined relative to the initial amount of coumarin 6 loaded into the polymer matrix. RG 502 has markedly higher release at each time interval and a faster release rate at early time points (Figure 3) . This is likely because these particles consist of a polymer with a smaller molecular weight that results in faster release rate. [35] Mechanistically, drug release from the PLGA NPs is a complicated process involving diffusion, hydrolysis, bulk erosion, and surface erosion, [21, 36, 37] giving rise to different degradation and release rates achieved by changing the end group or molecular weight of the PLGA. In contrast, nucleic acids are immobilized on the surface of the SNAs using the same attachment chemistry for each formulation and the dissociation rate of nucleic acids remains relatively constant for all formulations studied, which suggests that the governing mechanism of nucleic acid shell dissociation is the hydrolysis of the ester backbone defining the PLGA polymer.
To investigate the potential of the PLGA-SNA construct as a therapeutic platform, we synthesized PLGA-SNAs with Cy5-tagged T 20 oligonucleotides and quantified their cellular uptake in a Raw-Blue macrophage reporter cell line. As expected, the flow cytometry results showed that PLGA-SNAs readily enter the Raw-Blue cells ([DNA] = 100 × 10 −9 m, 2 h) without the use of toxic transfection agents (Figure 4A) . The cellular uptake of PLGA-SNAs into Raw-Blue cells is both time and dose dependent ( Figure 4B ), and at shorter times such as 0.5 h, the uptake of PLGA-SNAs is tenfold greater than their linear counterparts ( Figure 4B) . The biodegradable and biocompatible nature of PLGA confers no toxicity at concentrations ranging from 10 × 10 −9 m to 2 × 10 −6 m ( Figure 4C) . Last, to evaluate the ability of the PLGA-SNAs to act as a potential immunotherapy platform, we synthesized PLGA-SNAs bearing CpG motifs, a known agonist capable of engaging and activating TLR9. Significantly, PLGA-SNAs activate TLR9 in Raw-Blue cells in a dose-dependent manner, outperforming their linear counterparts throughout the concentration range studied ( Figure 4D ).
Taken together, we have demonstrated an extremely facile strategy for preparing a new class of SNAs under mild conditions that add different properties and functionalities to the existing SNA constructs utilizing click chemistry for surface functionalization (see Table S2 in the Supporting Information). This two-step method yields highly monodisperse PLGA-SNAs without the aggressive extrusion (often >10 rounds), time-consuming lyophilization of the lipid components, and freeze-thaw cycling (often >5 rounds) that are currently employed during liposomal SNA preparation. The drug-release kinetics of drugencapsulated PLGA-SNAs can be independently tuned without significantly changing the half-life of nucleic acids on the NPs. Moreover, this system provides another handle to further test our hypothesis that the unique properties of SNAs are in large part due to their 3D arrangement of linear nucleic acids and are core independent.
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